Advancing the Science in HER2-Positive Cancers
We are redefining what is possible in the treatment of cancer by improving on the standard of care across the oncology spectrum, and by focusing on innovative areas of research for patient communities with significant unmet needs, including those living with HER2-expressing cancers. HER2 plays an important role in cell growth and survival, but many cancers including biliary tract, gastric, breast and colorectal can overexpress this protein, leading to uncontrolled cell growth. Read more about HER2-protein expression and HER2-expressing cancers, how Jazz is working to advance treatment options for this community and hear stories from people living with the disease.
Advancements in HER2-Targeted Cancer Treatments: The Potential of Bispecific Antibodies
Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments.
Supporting Biliary Tract Cancer Patients Through Advocacy Partnerships
As we continue to advance our work in biliary tract cancer, we’re focused on reaching patients where they are, which will help inform our approach to R&D and better support patients throughout their care journeys with the resources they need. Partnering with advocacy organizations is one way to connect with patients directly, and in turn, gain insights that will enrich our efforts and help us tailor resources specifically to the needs of patient populations.
Leader Perspectives
